C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.105 AUD -1.34% Market Closed
Market Cap: 122.8m AUD

Cyclopharm Ltd
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cyclopharm Ltd
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Total Other Income
AU$669.7k
CAGR 3-Years
68%
CAGR 5-Years
N/A
CAGR 10-Years
52%
Somnomed Ltd
ASX:SOM
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Optiscan Imaging Ltd
ASX:OIL
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Austco Healthcare Ltd
ASX:AHC
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Cyclopharm Ltd
Glance View

Market Cap
122.8m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
3.28 AUD
Undervaluation 66%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Total Other Income?
Total Other Income
669.7k AUD

Based on the financial report for Dec 31, 2024, Cyclopharm Ltd's Total Other Income amounts to 669.7k AUD.

What is Cyclopharm Ltd's Total Other Income growth rate?
Total Other Income CAGR 10Y
52%

The average annual Total Other Income growth rates for Cyclopharm Ltd have been 68% over the past three years , and 52% over the past ten years .

Back to Top